Genetic variation in the natriuretic peptide system and heart failure

Heart Failure Reviews

Volumn 15, Issue 3, 2010, Pages 219-228

  Lanfear, David E ^a  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

BNP; Heart failure; Pharmacogenetics

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE RECEPTOR C; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; ATRIAL NATRIURETIC FACTOR RECEPTOR;

CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; NATRIURESIS; PHARMACOGENETICS; PROGNOSIS; REVIEW; GENETICS; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME;

ATRIAL NATRIURETIC FACTOR; GENETIC VARIATION; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; PHARMACOGENETICS; PREVALENCE; PROGNOSIS; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RISK FACTORS; TREATMENT OUTCOME;

EID: 77953190961     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9113-y     Document Type: Review

References (69)

1. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD (2002) Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39(1):60-69
2. American Heart Association (2004) Heart disease and stroke statistics - 2005 Update. http://www.americanheart.org/presenter.jhtml?identifier=1928. Accessed 2004
3. Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348(20):2007-2018
4. Popovic JR, Hall MJ (1999) National hospital discharge survey. Hyattsville, Maryland: Center for Disease Control, National Center for Health Statistics; 2001 April 24. Report No.: 319
5. Chen HH, Burnett JC Jr (1999) The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians 111(5):406-416
6. Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347(3):161-167
7. Scios JJ Nesiritide Prescribing Information P0101208
8. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K (2005) Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J 69(3):283-290
9. Nabel EG (2003) Cardiovascular disease. N Engl J Med 349(1):60-72
10. Evans WE, McLeod HL (2003) Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 348(6):538-549
11. Lanfear DE, McLeod HL (2007) Pharmacogenetics: using DNA to optimize drug therapy. Am Fam Physician 76(8):1179-1182
12. Nakayama T (2005) The genetic contribution of the natriuretic peptide system to cardiovascular diseases. Endocr J 52(1):11-21
13. LaPointe MC, Yang XP, Carretero OA, He Q (2002) Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector. Am J Physiol Heart Circ Physiol 283(4):H1439-H1445
14. Stoupakis G, Klapholz M (2003) Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. Heart Dis 5(3):215-223
15. Koller KJ, Goeddel DV (1992) Molecular biology of the natriuretic peptides and their receptors. Circulation 86(4):1081-1088
16. Almirez R, Protter AA (1999) Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity. J Pharmacol Exp Ther 289(2):976-980
17. Rose RA, Giles WR (2008) Natriuretic peptide C receptor (NPRC) signaling in the heart and vasculature. J Physiol 586(2):353-366
18. Kuhn M (2003) Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 93(8):700-709
19. Sabrane K, Kruse MN, Fabritz L et al (2005) Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest 115(6):1666-1674
20. Holtwick R, Gotthardt M, Skryabin B et al (2002) Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci USA 99(10):7142-7147
21. Ellmers LJ, Knowles JW, Kim HS, Smithies O, Maeda N, Cameron VA (2002) Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol 283(2):H707-H714
22. Ellmers LJ, Scott NJ, Piuhola J et al (2007) Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol 38(1-2):245-257
23. Vellaichamy E, Kaur K, Pandey KN (2007) Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. Peptides 28(4):893-899
24. Kapoun AM, Liang F, O'Young G et al (2004) B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94(4):453-461
25. John SW, Veress AT, Honrath U et al (1996) Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol 271(1 Pt 2):R109-R114
26. Lopez MJ, Wong SK, Kishimoto I et al (1995) Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378(6552):65-68
27. Tamura N, Ogawa Y, Chusho H et al (2000) Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97(8):4239-4244
28. Lanfear DE, Stolker J, Marsh S, Rich MW, McLeod HL (2006) Natriuretic Peptide Receptor 3 (NPR3) genotype modulates the relationship between B-Type Natriuretic Peptide (BNP) and left ventricular end-diastolic pressure. Therapy 3(6):765-771
29. Lanfear DE, Marsh S, McLeod HL (2004) Sequence variants of natriuretic peptide receptor C are common and their frequency differs between African Americans and European Americans. J Card Fail 10(4 Suppl):S59
30. Rahmutula D, Nakayama T, Soma M et al (2002) Structure and polymorphisms of the human natriuretic peptide receptor C gene. Endocrine 17(2):85-90
31. Rahmutula D, Nakayama T, Soma M et al (2001) Systematic screening of type B human natriuretic peptide receptor gene polymorphisms and association with essential hypertension. J Hum Hypertens 15(7):471-474
32. Sezaki N, Ishimaru F, Tabayashi T et al (2003) The type 1 CD10/neutral endopeptidase 24.11 promoter: functional characterization of the 5′-untranslated region. Br J Haematol 123(1):177-183
33. Wang TJ, Larson MG, Levy D et al (2003) Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 108(1):13-16
34. Knowles JW, Erickson LM, Guy VK, Sigel CS, Wilder JC, Maeda N (2003) Common variations in noncoding regions of the human natriuretic peptide receptor A gene have quantitative effects. Hum Genet 112(1):62-70
35. Nakayama T, Soma M, Saito S et al (2003) Missense mutation of exon 3 in the type A human natriuretic peptide receptor gene is associated with myocardial infarction. Med Sci Monit 9(12): CR505-CR510
36. Pitzalis MV, Sarzani R, Dessi-Fulgheri P et al (2003) Allelic variants of natriuretic peptide receptor genes are associated with family history of hypertension and cardiovascular phenotype. J Hypertens 21(8):1491-1496
37. Nakayama T, Soma M, Takahashi Y, Rehemudula D, Kanmatsuse K, Furuya K (2000) Functional deletion mutation of the 5′-flanking region of type A human natriuretic peptide receptor gene and its association with essential hypertension and left ventricular hypertrophy in the Japanese. Circ Res 86(8):841-845
38. Aoi N, Soma M, Nakayama T et al (2004) Variable number of tandem repeat of the 5′-flanking region of type-C human natriuretic peptide receptor gene influences blood pressure levels in obesity-associated hypertension. Hypertens Res 27(10):711-716
39. Tremblay J, Hum DH, Sanchez R et al (2003) TA repeat variation, Npr1 expression, and blood pressure: impact of the Ace locus. Hypertension 41(1):16-24
40. Rubattu S, Bigatti G, Evangelista A et al (2006) Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol 48(3):499-505
41. Lanfear DE, Stolker JM, Marsh S, Rich MW, McLeod HL (2007) Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther 21(1):55-62
42. Palmer BR, Frampton CM, Richards AM, Cameron VA, Nakayama T (2004) Absence of a NPR-A gene functional deletion allele in a postmyocardial infarction cohort from New Zealand. Circ Res 94(10):e86
43. Nakayama T, Soma M, Mizutani Y et al (2002) A novel missense mutation of exon 3 in the type A human natriuretic peptide receptor gene: possible association with essential hypertension. Hypertens Res 25(3):395-401
44. Rehemudula D, Nakayama T, Soma M et al (1999) Structure of the type B human natriuretic peptide receptor gene and association of a novel microsatellite polymorphism with essential hypertension. Circ Res 84(5):605-610
45. Vassalle C, Andreassi MG, Prontera C et al (2007) Influence of ScaI and natriuretic peptide (NP) clearance receptor polymorphisms of the NP System on NP concentration in chronic heart failure. Clin Chem 53(11):1886-1890
46. Sarzani R, Dessi-Fulgheri P, Salvi F et al (1999) A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower atrial natriuretic peptide and higher blood pressure in obese hypertensives. J Hypertens 17(9):1301-1305
47. Helisalmi S, Hiltunen M, Vepsalainen S et al (2004) Polymorphisms in neprilysin gene affect the risk of Alzheimer's disease in Finnish patients. J Neurol Neurosurg Psychiatry 75(12):1746-1748
48. Lilius L, Forsell C, Axelman K, Winblad B, Graff C, Tjernberg L (2003) No association between polymorphisms in the neprilysin promoter region and Swedish Alzheimer's disease patients. Neurosci Lett 337(2):111-113
49. Nkeh B, Tiago A, Candy GP et al (2002) Association between an atrial natriuretic peptide gene polymorphism and normal blood pressure in subjects of African ancestry. Cardiovasc J S Afr 13(3):97-101
50. Rubattu S, Stanzione R, Di Angelantonio E et al (2004) Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 35(4):814-818
51. Meirhaeghe A, Sandhu MS, McCarthy MI et al (2007) Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet 16(11):1343-1350
52. Kosuge K, Soma M, Nakayama T et al (2007) A novel variable number of tandem repeat of the natriuretic peptide precursor B gene's 5′-flanking region is associated with essential hypertension among Japanese females. Int J Med Sci 4(3):146-152
53. Chiu C, Ingles J, Lind JM, Semsarian C (2006) Mutation analysis of the natriuretic peptide precursor B (NPPB) gene in patients with hypertrophic cardiomyopathy. DNA Seq 17(5):392-395
54. Tiret L, Mallet C, Poirier O et al (2000) Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol 35(1):29-35
55. Maisel AS, Clopton P, Krishnaswamy P et al (2004) Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 147(6):1078-1084
56. Mak GS, DeMaria A, Clopton P, Maisel AS (2004) Utility of Bnatriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings. Am Heart J 148(5):895-902
57. de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362(9380):316-322
58. Stolker JM, Rich MW (2005) B-type natriuretic peptide provides independent and incremental value in predicting left ventricular end-diastolic pressure in elderly patients. Am J Geriatric Cardiol 14(2 Suppl):109
59. Stolker JM, Rich MW (2005) The combination of B-type natriuretic peptide and C-reactive protein provides incremental value in predicting outcomes among older patients referred for cardiac catheterization. Am J Geriatric Cardiol 14(2):109-110
60. Drazner MH, de Lemos JA (2005) Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. Am Heart J 149(2):187-189
61. Troughton RW, Prior DL, Pereira JJ et al (2004) Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43(3):416-422
62. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M (1998) Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135(5 Pt1):825-832
63. LaPointe MC (2005) Molecular regulation of the brain natriuretic peptide gene. Peptides 26(6):944-956
64. Waldo SW, Beede J, Isakson S et al (2008) Pro-B-type natriuretic peptide levels in acute decompensated heart failure. J Am Coll Cardiol 51(19):1874-1882
65. Colucci WS, Elkayam U, Horton DP et al (2000) Intravenousnesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343(4):246-253
66. VMAC Study Group (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287(12):1531-1540
67. Silver MA, Horton DP, Ghali JK, Elkayam U (2002) Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 39(5):798-803
68. Sackner-Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111(12):1487-1491
69. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293(15):1900-1905